RedHill Biopharma shares erase gains after company announces stock offering
By Ciara Linnane
Stock gained early Friday on news of government funding for a treatment for radiation sickness
RedHill Biopharma Ltd.'s stock soared 10% early Friday after the company announced fresh U.S. government funding to help it and partner Apogee develop a treatment for radiation sickness.
But the stock quickly reversed those gains after the Tel Aviv-based company (RDHL) announced a direct offering of 1.3 million of its U.S.-listed shares at a discounted price of $1.35 per American depositary share and an agreement to exercise warrants for 1.5 million ADSs at the same price.
The stock was last down 21% at $1.47 and was on track for its worst one-day performance since March 17, when it fell 24%.
RedHill said it has received an additional $1.7 million in U.S. government funding to develop a treatment for gastrointestinal acute radiation syndrome.
The grant from the Small Business Innovation Research fund will go to develop opaganib, an oral small-molecule pill with a five-year shelf life.
The treatment is being developed using animal-model efficacy studies as the basis for approval by the U.S. Food and Drug Administration, instead of human efficacy trials.
"In light of ongoing regional geopolitical instabilities, it is important for us to bring together all the pieces of the development jigsaw for opaganib as a potential medical countermeasure for acute radiation syndrome," said RedHill CEO Dror Ben-Asher.
The pill is easy to administer and distribute and, if it wins FDA approval, would support government stockpiling for use in mass-casualty radiological or nuclear incidents, he said.
Radiation sickness is rare but could affect large numbers of people in the event of a nuclear accident or attack, he said.
The company has also received funding from the U.S. Government Radiation and Nuclear Countermeasures Program.
Ben-Asher said opaganib is also being evaluated as a treatment for COVID-19 and other indications. RedHill's pipeline includes treatments for other gastrointestinal and infectious diseases and for cancers.
The direct offering and warrant exercise will raise $3.8 million in gross proceeds, which will be used for general working capital, acquisitions, research and development and general corporate purposes, according to the company. H.C. Wainwright acted as sole placement agent for the deals.
RedHill's U.S.-listed stock has fallen 67% in the year to date, while the S&P 500 has gained 18%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-21-23 1050ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom